Journal
NEUROIMAGE-CLINICAL
Volume 2, Issue -, Pages 356-365Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.nicl.2013.02.006
Keywords
Amyloid PET imaging; Cognitively normal elderly; Preclinical Alzheimer's disease; Subjective cognitive decline; ApoE4; Longitudinal studies
Categories
Funding
- Agence Nationale de la Recherche (ANR)
- Programme Hospitalier de Recherche Clinique (PHRC National)
- Fondation Plan Alzheimer
- Region Basse Normandie
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- FWO [G.0076.02]
- KU Leuven Research [OT/08/056, OT/12/097]
- Federaal Wetenschapsbeleid belspo Inter-University Attraction Pole [P6/29, P7/11]
- Stichting Alzheimer Onderzoek [11020]
Ask authors/readers for more resources
Recent developments of PET amyloid ligands have made it possible to visualize the presence of A beta deposition in the brain of living participants and to assess the consequences especially in individuals with no objective sign of cognitive deficits. The present review will focus on amyloid imaging in cognitively normal elderly, asymptomatic at-risk populations, and individuals with subjective cognitive decline. It will cover the prevalence of amyloid-positive cases amongst cognitively normal elderly, the influence of risk factors for AD, the relationships to cognition, atrophy and prognosis, longitudinal amyloid imaging and ethical aspects related to amyloid imaging in cognitively normal individuals. Almost ten years of research have led to a few consensual and relatively consistent findings: some cognitively normal elderly have A beta deposition in their brain, the prevalence of amyloid-positive cases increases in at-risk populations, the prognosis for these individuals is worse than for those with no A beta deposition, and significant increase in A beta deposition over time is detectable in cognitively normal elderly. More inconsistent findings are still under debate; these include the relationship between A beta deposition and cognition and brain volume, the sequence and cause-to-effect relations between the different AD biomarkers, and the individual outcome associated with an amyloid positive versus negative scan. Preclinical amyloid imaging also raises important ethical issues. While amyloid imaging is definitely useful to understand the role of A beta in early stages, to define at-risk populations for research or for clinical trial, and to assess the effects of anti-amyloid treatments, we are not ready yet to translate research results into clinical practice and policy. More researches are needed to determine which information to disclose from an individual amyloid imaging scan, the way of disclosing such information and the impact on individuals and on society. (C) 2013 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available